XML 67 R55.htm IDEA: XBRL DOCUMENT v3.21.1
License Agreements - MorphoSys (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Mar. 03, 2020
Mar. 31, 2020
Jan. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Long term investments       $ 202,174   $ 222,301 [1]
Research and development expense       306,896 $ 1,085,287  
Unrealized loss on long term investments       (27,709) (48,132)  
Collaboration loss sharing       10,484 2,130  
ADSs            
Equity Method Investment, Ownership Percentage     25.00%      
Equity Method Investment, Aggregate Cost     $ 150,000      
Per share price $ 27.65   $ 41.33      
Lock-up period     18 months      
Discount for lack of marketability $ 4,900          
Fair value of shares 95,500     $ 79,100   102,900
Long term investments 95,500          
Research and development expense $ 54,500          
MorphoSys AG            
Upfront payment under license agreement   $ 750,000        
Equity Method Investment, Ownership Percentage       3.00%    
Research and development expense       $ 14,900 11,600  
Unrealized loss on long term investments       $ (23,700) $ (9,900)  
Profit (loss) sharing ratio       50.00% 50.00%  
Collaboration loss sharing       $ 10,500 $ 2,100  
MorphoSys AG | Accrued and other liabilities            
Accrued and other liabilities       $ 47,200   $ 54,200
MorphoSys AG | Development and Regulatory Milestones | Maximum            
Additional milestone payments under the license agreement     $ 740,000      
MorphoSys AG | Sales and Commercial Milestones | Maximum            
Additional milestone payments under the license agreement     $ 315,000      
MorphoSys AG | MorphoSys AG            
Funding of future development costs (as a percent)     45.00%      
MorphoSys AG | Incyte            
Funding of future development costs (as a percent)     55.00% 55.00%    
[1] The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements at that date.